Abstract
Calcium Release-Activated Calcium (CRAC) channel is a highly Ca2+-selective store-operated channel constituted by two-component mediators (STIM and ORAI) and controls a wide range of cellular functions in various tissues. Gain-of-function (GoF) mutations of CRAC channel cause excessive Ca2+ entry, which can lead to serious diseases such as tubular aggregate myopathy and Stormorken syndrome (TAM/STRMK). To solve this problem and to gain precise control of the CRAC channel, we have designed both an optogenetic and a chemogenetic strategy for engineering of CRAC channel blockers (designated Opto-CRAB and Chemo-CRAB), which can mediate Ca2+ influx and Ca2+-dependent signaling such as NFAT induced gene expression and T cell activation. Beyond in vitro applications, both Opto-CRAB and Chemo-CRAB have been applied in vivo experiments in a zebrafish model of Stormorken syndrome that resulted in the mitigation of thrombocytopenia and hemorrhage in light and chemical dependent manners. Welch Foundation (BE-1913-20220331 to Y.Z.), Leukemia & Lymphoma Society (LLS6680-24 to Y.Z.), the National Institutes of Health (R01GM144986 to Y.Z. and R21AI174606 to Y.Z.). This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
